Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy

Movement Disorders

Volumn 22, Issue 3, 2007, Pages 353-358

  Köllensperger, Martin ^a   Stefanova, Nadia ^a   Reindl, Markus ^a   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Behavior; L dopa response; MSA P

Indexed keywords

LEVODOPA; OXIDOPAMINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; GAIT DISORDER; HISTOPATHOLOGY; MALE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA;

ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MULTIPLE SYSTEM ATROPHY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 34147174313     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21251     Document Type: Article

References (30)

1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
2. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990;113(Pt 6):1823-1842.
3. Churchyard A, Donnan GA, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993;34:219-226.
4. Quinn NP, Marsden CD. The motor disorder of multiple system atrophy. J Neurol Neurosurg Psychiatry 1993;56:1239-1242.
5. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005;28:501-506.
6. Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioral abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 1996;11:522-532.
7. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15:3863-3875.
8. Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 2004;15:630-639.
9. Scherfler C, Puschban Z, Ghorayeb I, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000;99:43-54.
10. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000;39:777-787.
11. Puschban Z, Stefanova N, Petersen A, et al. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. Brain Res Bull 2005;68:54-58.
12. Blunt SB, Jenner P, Marsden CD. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Res 1992;582:299-311.
13. Kirik D, Winkler C, Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 2001;21:2889-2896.
14. Nakao N, Brundin P. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience 1997;76:749-761.
15. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
16. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117(Pt 4):835-845.
17. Goto S, Matsumoto S, Ushio Y, Hirano A. Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration. Neurology 1996;47:1032-1036.
18. Puschban Z, Scherfler C, Granata R, et al. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience 2000;95:377-388.
19. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
20. Flicker RA, Annett LE, Torres EM, Dunnett SB. The placement of a striatal ibotenic acid lesion affects skilled forelimb use and the direction of drug-induced rotation. Brain Res Bull 1996;41:409-416.
21. Norman AB, Norgren RB, Wyatt LM, Hildebrand JP, Sanberg PR. The direction of apomorphine-induced rotation behavior is dependent on the location of excitotoxin lesions in the rat basal ganglia. Brain Res 1992;569:169-172.
22. Pisa M, Schranz JA. Dissociable motor roles of the rat's striatum conform to a somatotopic model. Behav Neurosci 1988;102:429-440.
23. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999;56:90-94.
24. Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991;1:9-13.
25. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117(Pt 2):235-243.
26. Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999;9:721-732.
27. Fillon G, Kahle PJ. Alpha-synuclein transgenic mice: relevance to multiple system atrophy. Mov Disord 2005;20(Suppl. 12):S64-S66.
28. Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005;25:10689-10699.
29. Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166:869-876.
30. Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847-859.